1
Rose A Persichetti, Scott L Harbeson: Substituted morpholinyl compounds. Concert Pharmaceuticals, Fish & Richardson P C, May 5, 2009: US07528131 (108 worldwide citation)

This disclosure relates to novel substituted morpholinyl compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating dis ...


2
Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer: Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Vertex Pharmaceuticals Incorporated, James F Haley, Lisa A Dixon, Fish & Neave, July 24, 2001: US06265380 (85 worldwide citation)

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhi ...


3
Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer: Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Vertex Pharmaceuticals Incorporated, James F Haley Jr, Kyumin K Lee, Fish & Neave, September 9, 2003: US06617309 (65 worldwide citation)

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhi ...


4
Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer: Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Vertex Pharmaceuticals Incorporated, Ropes & Gray, James F Haley Jr, David A Roise, June 17, 2008: US07388017 (49 worldwide citation)

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhi ...


5
Scott L Harbeson, Julie A Straub: Optically pure calpain inhibitor compounds. Townsend and Townsend and Crew, July 30, 1996: US05541290 (15 worldwide citation)

Optically pure .alpha.-ketoamide compounds, and use therefor in treating neurodegenerative pathologies having enhanced Calpain activity, are disclosed. These compounds comprise optically pure .alpha.-ketoamides, and physiologically acceptable salts thereof, wherein the .alpha.-ketoamide contains an ...


6
Roger D Tung, Julie F Liu, Scott L Harbeson: Deuterium substituted xanthine derivatives. CoNCERT Pharmaceuticals, McCarter & English, Stephen G Davis, September 11, 2012: US08263601 (14 worldwide citation)

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are derivatives of a pentoxifylline metabolite. This invention also provides composi ...


7
Guy W Bemis, Scott L Harbeson, Mark Ledeboer: Inhibitors of JAK protein kinase. Vertex Pharmaceuticals Incorporated, Karen E Brown, September 18, 2007: US07271179 (11 worldwide citation)

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.


8
Jon H Come, Jeremy Green, Craig Marhefka, Scott L Harbeson, Ly Pham: Aminofurazan compounds useful as protein kinase inhibitors. Vertex Pharmaceuticals Incorporated, Daniel A Pearson, Vertex Pharmaceuticals Incorporated, January 2, 2007: US07157476 (10 worldwide citation)

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.


9
Roger D Tung, Julie F Liu, Scott L Harbeson: Deuterium-substituted xanthine derivatives and methods of use. Concert Pharmaceuticals, McCarter & English, Steven G Davis, Emily Dertz, March 24, 2015: US08987442 (8 worldwide citation)

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprisin ...


10
Scott L Harbeson, Alan J Bitonti: Cyclic Antiplatelet peptides with pseudo-bond. Merrell Pharmaceuticals, T Helen Payne, August 22, 2000: US06107275 (6 worldwide citation)

The present invention relates to cyclic peptide analogs containing a pseudo-bond, useful as platelet aggregation inhibitors. An example of a compound of this invention includes Cyclo[Ala.PSI.[CH.sub.2 NH]-Arg-Gly-Asp-.delta.-Glu](NHBn).cndot.CF.sub.3 CO.sub.2 H. These compounds inhibit the binding o ...